Fosun Pharma Buys Back 1.34 Million H-Shares for HKD 21.86 Million, Raising Treasury Stock to 14.37 Million Shares

Bulletin Express09-11 17:44

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026.

Key transaction details • Volume and proportion: 1.34 million H-shares, representing 0.25% of the company’s issued share capital (excluding treasury shares) prior to the transaction. • Price range: HKD 16.14 to HKD 16.50 per share; volume-weighted average price of HKD 16.32. • Consideration: HKD 21.86 million.

Impact on share capital structure (H-shares) • Issued shares (excluding treasury shares) decreased from 538.91 million to 537.57 million. • Treasury shares rose from 13.03 million to 14.37 million. • Total issued shares remained unchanged at 551.94 million.

Repurchase mandate utilisation • Authorised limit: 54.10 million shares. • Cumulative repurchases under the mandate: 3.40 million shares, equal to 0.63% of the issued share count on the mandate date. • Remaining authority: 50.69 million shares.

Post-transaction restrictions In accordance with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on new share issues or treasury share disposals until 11 October 2026.

The company confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the explanatory statement issued on 11 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116515297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116515297","market":"hk","top_or_hot":-1,"title":"Fosun Pharma Buys Back 1.34 Million H-Shares for HKD 21.86 Million, Raising Treasury Stock to 14.37 Million Shares","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026.</p>\n<p>Key transaction details  \n• Volume and proportion: 1.34 million H-shares, representing 0.25% of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 16.14 to HKD 16.50 per share; volume-weighted average price of HKD 16.32.  \n• Consideration: HKD 21.86 million.</p>\n<p>Impact on share capital structure (H-shares)  \n• Issued shares (excluding treasury shares) decreased from 538.91 million to 537.57 million.  \n• Treasury shares rose from 13.03 million to 14.37 million.  \n• Total issued shares remained unchanged at 551.94 million.</p>\n<p>Repurchase mandate utilisation  \n• Authorised limit: 54.10 million shares.  \n• Cumulative repurchases under the mandate: 3.40 million shares, equal to 0.63% of the issued share count on the mandate date.  \n• Remaining authority: 50.69 million shares.</p>\n<p>Post-transaction restrictions  \nIn accordance with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on new share issues or treasury share disposals until 11 October 2026.</p>\n<p>The company confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the explanatory statement issued on 11 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Buys Back 1.34 Million H-Shares for HKD 21.86 Million, Raising Treasury Stock to 14.37 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Buys Back 1.34 Million H-Shares for HKD 21.86 Million, Raising Treasury Stock to 14.37 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-11 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026.</p>\n<p>Key transaction details  \n• Volume and proportion: 1.34 million H-shares, representing 0.25% of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 16.14 to HKD 16.50 per share; volume-weighted average price of HKD 16.32.  \n• Consideration: HKD 21.86 million.</p>\n<p>Impact on share capital structure (H-shares)  \n• Issued shares (excluding treasury shares) decreased from 538.91 million to 537.57 million.  \n• Treasury shares rose from 13.03 million to 14.37 million.  \n• Total issued shares remained unchanged at 551.94 million.</p>\n<p>Repurchase mandate utilisation  \n• Authorised limit: 54.10 million shares.  \n• Cumulative repurchases under the mandate: 3.40 million shares, equal to 0.63% of the issued share count on the mandate date.  \n• Remaining authority: 50.69 million shares.</p>\n<p>Post-transaction restrictions  \nIn accordance with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on new share issues or treasury share disposals until 11 October 2026.</p>\n<p>The company confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the explanatory statement issued on 11 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1116515297","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116515297","pubTimestamp":1789119880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026. Key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药以2186万港元回购134万股H股，库存股增至1437万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026.\nKey transaction details  \n• Volume and proportion: 1.34 million H-shares, representing 0.25% of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 16.14 to HKD 16.50 per share; volume-weighted average price of HKD 16.32.  \n• Consideration: HKD 21.86 million.\nImpact on share capital structure (H-shares)  \n• Issued shares (excluding treasury shares) decreased from 538.91 million to 537.57 million.  \n• Treasury shares rose from 13.03 million to 14.37 million.  \n• Total issued shares remained unchanged at 551.94 million.\nRepurchase mandate utilisation  \n• Authorised limit: 54.10 million shares.  \n• Cumulative repurchases under the mandate: 3.40 million shares, equal to 0.63% of the issued share count on the mandate date.  \n• Remaining authority: 50.69 million shares.\nPost-transaction restrictions  \nIn accordance with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on new share issues or treasury share disposals until 11 October 2026.\nThe company confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the explanatory statement issued on 11 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116515297","isCrawlerRequest":true}